Biotech Values

[drbio45]

cycc

the ceo got the stock to move from the twenty cent range by showing that his drug was better than Genzyme's and Vion's that were in front of the FDA with open label phase 2 data, and he intimated he could do the same thing.

when the odac panel meeting was exposed showing that the fda advised genzyme that they didn't want open label phase 2 data in the first place I was surprised that cycc was able to stay near a dollar

It is going to take a long time to run a randomized phase 3 study. They will have to dilute quite a bit. Not sure how the preferred stock effects the equation.